Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELODY: Maintenance Pegylated Liposomal Doxorubicin vs Active Surveillance in Advanced Soft Tissue Sarcoma
NCT06981637Phase 2Recruiting
- Sponsor
- National Health Research Institutes
- Start
- Dec 2025
- Primary completion
- Jul 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegylated liposomal doxorubicin in soft tissue sarcoma (STS) (2 arms), sponsored by National Health Research Institutes. Primary endpoint: Progression-Free Survival at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06981637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06981637.